

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai-400018

Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30<sup>th</sup> SEPTEMBER, 2016

₹ In Lakhs

Sr. No.	Particulars	Unaudited					Audited
		3 months ended 30/9/2016	Preceding 3 months ended 30/06/2016	Corresponding 3 months ended in the previous year 30/09/2015	Year to date figures for Current period ended 30/09/2016	Year to date figures for previous period ended 30/09/2015	Previous year ended 31/03/2016
<b>PART-I</b>							
1	Income From Operations						
a	Net Sales/ Income from Operations (Net of Excise duty)	5,006.78	4,800.91	8,974.61	9,807.69	17,530.67	32,063.07
b	Other Operating Income	13.23	109.54	156.37	122.77	264.25	559.10
	Total income from Operations (net):-	5,020.01	4,910.45	9,130.98	9,930.46	17,794.92	32,622.17
2	Expenditure						
a	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(127.11)	116.48	(174.85)	(10.63)	(565.88)	(253.36)
b	Cost of Materials Consumed	3,754.95	3,604.65	7,014.39	7,359.60	14,003.87	24,892.62
c	Purchase of Stock -in-Trade	-	-	-	-	-	227.75
d	Employee Benefits Expense	158.86	178.09	171.42	336.95	327.99	657.74
e	Processing Charges	192.24	204.01	174.39	396.25	380.07	803.87
f	Power Fuel & Other Utility	72.67	71.83	105.95	144.50	192.32	347.68
g	Depreciation and amortisation expenses	41.65	51.35	54.87	93.00	105.37	225.88
h	Other Expenses	325.92	289.54	523.15	615.46	969.67	2,017.58
	Total Expenses :-	4,419.19	4,515.95	7,869.33	8,935.14	15,413.40	28,919.76
3	Profit From Operations before other income, Finance Costs & Exceptional Items (1-2)	600.82	394.50	1,261.65	995.31	2,381.53	3,702.41
4 a	Other Income	102.26	132.25	52.75	234.51	159.53	350.65
b	Exchange Gain/(Loss)	(6.31)	3.70	(156.22)	(2.61)	(215.51)	(255.11)
5	Profit from ordinary activities before finance costs & Exceptional Items (3+4)	696.76	530.45	1,158.18	1,227.21	2,325.55	3,797.96
6	Finance Costs	0.77	0.31	0.17	1.08	0.23	4.25
7	Profit from ordinary activities after finance costs but before Exceptional Items (5-6)	695.99	530.14	1,158.01	1,226.13	2,325.32	3,793.71
8	Exceptional Items	-	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before Tax (7+8)	695.99	530.14	1,158.01	1,226.13	2,325.32	3,793.71
10	Tax Expenses	209.00	141.00	415.00	350.00	780.00	1,213.28
11	Net Profit / (Loss) from ordinary activities after Tax (9-10)	486.99	389.14	743.01	876.13	1,545.32	2,580.43
12	Extraordinary Item (Net of Tax Expenses)	-	-	-	-	-	-
13	Profit / (Loss) for the period after Tax (after Extra ordinary items)	486.99	389.14	743.01	876.13	1,545.32	2,580.43
14	Share of profit / (Loss) of associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	Net Profit(+) / Loss(-) after taxes, minority interest and share of profit of profit / (loss) of associates (13+14+15)	486.99	389.14	743.01	876.13	1,545.32	2,580.43
17	Paid up Equity Share Capital ( Face value of ₹ 5/- each)	1,252.80	1,252.80	1,252.80	1,252.80	1,252.80	1,252.80
18	Reserves excluding Revaluation Reserves as per Balance sheet of Previous Accounting Year						10,674.99
19	Earnings per Share(EPS) Face Value of Rs.5/-						
	Earnings Per Share(before and after Extraordinary items) (not annualised)						
	(a) Basic	1.94	1.55	2.97	3.50	6.17	10.30
	(b) Diluted	1.94	1.55	2.97	3.50	6.17	10.30

1 The above Financial Results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their Meeting held on 11<sup>th</sup> November, 2016.

2 The Company's operation fall under single segment namely "Bulk Drugs & Chemicals".

3 The above is an extract of the detailed format of Financial Results for the Quarter and Half year ended on 30<sup>th</sup> September, 2016, filed with the Stock Exchange as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Half year ended on 30<sup>th</sup> September, 2016 is available on the Stock Exchange website viz. www.bseindia.com and on the Company's website i.e. www.anuhpharma.com.

4 Corresponding figures of the previous quarter have been regrouped, to make them comparable wherever necessary.

Place : Mumbai

Date : 11<sup>th</sup> NOVEMBER, 2016

FOR ANUH PHARMA LIMITED

*P. Prasad*

Managing Director

**ANUH PHARMA LIMITED**  
**STATEMENT OF ASSETS & LIABILITIES**

₹ In Lakhs

Particulars	As at September 30, 2016 Unaudited	As at March 31, 2016 Audited
	₹	₹
<b>I. EQUITY AND LIABILITIES</b>		
<b>1 Shareholders' funds</b>		
(a) Share capital	1,253	1,253
(b) Reserves and surplus	11,408	10,675
(c) Money received against share warrants	-	-
	12,660	11,928
<b>2 Share application money pending allotment</b>		
<b>3 Non-current liabilities</b>		
(a) Long-term borrowings	-	-
(b) Deferred tax liabilities (net)	-	-
(c) Other long term liabilities	-	-
(d) Long-term provisions	93	78
	93	78
<b>4 Current liabilities</b>		
(a) Short-term borrowings		211
(b) Trade payables	3,779	5,232
(c) Other current liabilities	476	272
(d) Short-term provisions	1,668	1,533
	5,923	7,248
<b>TOTAL</b>	<b>18,677</b>	<b>19,254</b>
<b>II. ASSETS</b>		
<b>Non-current assets</b>		
<b>1 (a) Fixed assets</b>		
(i) Tangible assets	1,727	1,789
(ii) Intangible assets	40	42
(iii) Capital work-in-progress	19	19
(iv) Intangible assets under development	-	-
	1,786	1,850
(b) Non-current investments	2,790	2,103
(c) Deferred tax assets (net)	114	114
(d) Long-term loans and advances	89	84
(e) Other non-current assets	26	-
	3,018	2,300
<b>2 Current assets</b>		
(a) Current investments	3,997	2,195
(b) Inventories	1,853	2,369
(c) Trade receivables	5,383	7,467
(d) Cash and bank balances	739	1,338
(e) Short-term loans and advances	1,884	1,718
(f) Other current assets	16	16
	13,872	15,104
<b>TOTAL</b>	<b>18,677</b>	<b>19,254</b>

Place : Mumbai  
Date : 11<sup>TH</sup> NOVEMBER, 2016

For ANUH PHARMA LIMITED

*Anushal*

Managing Director



73-B MITTAL COURT, NARIMAN POINT, MUMBAI 400021, INDIA

TEL : (91 22) 22842093, 22842159 | FAX : (91 22) 22822743 | E-MAIL : SIMCO@SIMOGUL.COM | WEBSITE : SIMOGUL.COM

## LIMITED REVIEW REPORT

### TO THE BOARD OF DIRECTORS OF ANUH PHARMA LIMITED

We have reviewed the accompanying statement of unaudited financial results of **Anuh Pharma Limited** ("**Company**") for the period ended on September 30, 2016 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement ("**SRE**") 2400, '*Engagements to Review Financial Statements*' issued by the Institute of Chartered Accountants of India ("**ICAI**"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Mumbai, India: November 11, 2016

For **S. I. MOGUL & CO.**  
Chartered Accountants  
Firm Registration No. 106512W

*S. I. Mogul*

**S. I. Mogul**  
Partner

Membership No. 5572